---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Humanistic burden and health-related quality of life. Topics: Pain, fatigue, depression, and EQ-5D and SF-36 scores: systematic review of 7 humanistic burden studies; EQ-5D-5L utility, fatigue, and disability in 1056 patients from eight countries, including the United States; EQ-5D-3L utility and work productivity in 146 patients stable on immunoglobulin in the United States, the United Kingdom, and Germany; Health-state utility values by adjusted INCAT impairment level from EQ-5D data collected in ADHERE; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Pain, fatigue, depression, and EQ-5D and SF-36 scores: systematic review of 7 humanistic burden studies

> “Humanistic burden studies reported on the patient impact of CIDP on health-related quality of life (HRQoL), functioning, psychosocial welfare, productivity, pain, and fatigue”
> “2009 assessed pain and fatigue, using the Numeric Pain Rating Scale (NPRS) and Fatigue Severity Scale (FSS) scores (n = 76), reporting that 17 and 74% of patients with CIDP reported severe pain and severe fatigue, respectively”
> “Two publications reported that 9 and 12.1% of patients had depression, based on hospital anxiety and depression scale (HADS) and the Beck Depression Inventory version II (BDI-II) scores in The Netherlands and Germany, respectively”
> “EuroQol-5D (EQ-5D) scores among patients with CIDP were 0.62 and 0.68 for the UK and Germany, respectively”
> “A study of Dutch patients with CIDP (n = 76) also identified that patients scored below normative 36-Item Short Form Survey Instrument (SF-36) scores (50) for all the domains of the physical component and two of the domains of the mental component (vitality and social functioning)”

Source: [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/)

<a id="topic-2.2.1.8.1-2"></a>

### EQ-5D-5L utility, fatigue, and disability in 1056 patients from eight countries, including the United States

> “Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross‐sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023.”
> “Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self‐reported data.”
> “Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.”
> “Based on mean EQ‐5D‐3L norms in the UK (0.856) and mean EQ‐5D‐5L norms in Germany (0.88), patients experience lower HRQoL in comparison to the general population”
> “Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.8.1-3"></a>

### EQ-5D-3L utility and work productivity in 146 patients stable on immunoglobulin in the United States, the United Kingdom, and Germany

> “Overall, 146 patients, 52 caregivers, and 81 physicians completed the survey; mean (standard deviation) patient age was 58.1 (12.8) years; time since CIDP diagnosis was 8.8 (9.3) years; 98.6% had received IVIG, and 30.8% had received SCIG.”
> “Mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores in the patient cohort were 0.68 (0.23) and 62.3 (19.4), respectively.”
> “Patients reported that CIDP prevented them (quite a bit or very much) from performing activities (50.7%), affected their social activities with family and friends (39.7%), and imposed financial burden (37.7%).”
> “Among patients who were currently employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 37.9% (26.6)”

Source: [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

<a id="topic-2.2.1.8.1-4"></a>

### Health-state utility values by adjusted INCAT impairment level from EQ-5D data collected in ADHERE

> “In the company’s model, the health state utility values were informed by EQ-5D-5L data collected in ADHERE.”
> “The company estimated the following utility values for each health state:”
> “0.851 for very limited impairment”
> “0.630 for mild impairment”
> “0.426 for moderate impairment”
> “0.084 for severe impairment”
> “-0.216 for very severe impairment.”
> “The EAG explained that the utility values for very severe health states lacked face validity and were too low.”

Source: [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2)

<a id="topic-2.2.1.8.1-5"></a>

### SF-36 improvement with immune globulin IV 10% versus placebo in 117 trial participants

> “One hundred seventeen patients in a randomized, double-blind, response-conditional crossover trial received immune globulin IV, 10% caprylate/chromatography purified (IGIV-C [Gamunex(R)]), or placebo every 3 weeks for up to 24 weeks in the first period (FP).”
> “In the FP, greater improvements in both SF-36 physical and mental component scores were observed with IGIV-C vs placebo, with a significant improvement in the physical component score (difference 4.4 points; 95% confidence interval [CI] 0.7-8.0).”
> “In the EP, mean SF-36 improvements were generally improved or maintained in participants who continued IGIV-C therapy; however, worsening was observed in participants re-randomized to placebo.”

Source: [Merkies et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19365055/)

<a id="topic-2.2.1.8.1-6"></a>

### Health-related quality of life measures in chronic inflammatory neuropathies: systematic review

> “There is some evidence suggesting that baseline pre-treatment HRQoL reports are lower in patients with chronic inflammatory neuropathy than in age and gender-matched controls.”
> “Following treatment interventions, improvements in self-reported measures were consistently documented in the physical domain of HRQoL, which in turn correlated with improvements in traditional strength and functional scales.”
> “The impact of available treatments on the quality of life of patients with inflammatory neuropathies remains largely under-investigated.”

Source: [Rajabally and Cavanna (2015)](https://pubmed.ncbi.nlm.nih.gov/25467139/)

<a id="topic-2.2.1.8.1-7"></a>

### Changes in work and home life in a global survey of 595 respondents with self-reported CIDP

> “Data from an online survey of 595 individuals with self-reported CIDP, recruited by the Guillain–Barré syndrome (GBS)/CIDP Foundation, were used to assess disease and treatment burden.”
> “In "likely" CIDP patients 44% stopped working because of their symptoms and 24% moved to a new home.”
> “IVIg was associated with venous access issues and work/school absenteeism.”
> “CIDP diagnostic confirmation was not performed in any of the survey respondents.”

Source: [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
